Sølling, Anne Sophie http://orcid.org/0000-0001-7252-8128
Harsløf, Torben http://orcid.org/0000-0002-8581-3523
Jørgensen, Niklas Rye http://orcid.org/0000-0001-9624-5210
Langdahl, Bente http://orcid.org/0000-0002-8712-7199
Funding for this research was provided by:
Amgen (-)
The Danish Osteoporosis Society (-)
P. Carl Petersen’s Foundation (-)
Ekspeditionssekretær Cand.Jur. Torkil Steenbecks Legat (-)
Vilhelm Pedersen and wife’s Foundation (-)
Sundhedsvidenskabelige Fakultet, Aarhus Universitet (-)
Article History
Received: 31 May 2022
Accepted: 14 December 2022
First Online: 22 December 2022
Declarations
:
: Torben Harsløf received lecture fees from Amgen, Astra Zeneca, and Eli Lilly. Bente Langdahl has received research funding to her institution from Amgen and Novo Nordisk. Bente Langdahl serves on advisory boards and speaker’s bureau for Amgen, UCB, Gilead, and Gedeon-Richter. Niklas Rye Jørgensen has no conflicts of interest relevant to the current study. Anne Sophie Sølling received lecture fees from Amgen and Gedeon-Richter.
: After completion of the study, the participants received written information about the results. Also, the participants can seek further information about the project by contacting the investigator.